pharma · Idiopathic Pulmonary Fibrosis · Prevention of breast cancer in women with a BRCA1 germline mutation
Shanghai Zerun Biotechnology
Shanghai Reinovax Biologics Co.,LTD
Shanghai Zerun Biotechnology is a pharma organization headquartered in Shanghai, CN. Primary therapeutic focus areas include Idiopathic Pulmonary Fibrosis, Prevention of breast cancer in women with a BRCA1 germline mutat
Company details
- Status
- Public
- HQ
- 936号 Zhangheng Rd, Shanghai 201203, CN
- Employees
- 21
- Programs
- 11
- Drugs
- 33
- Patents
- 11
ABCSG 45
Phase 2 · small molecule · Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)
ABCSG 45 for Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test) is a Phase 2 program (small_molecule) at Shanghai Reinovax Biologics Co.,LTD with 1 ClinicalTrials.gov record(s).
Internal code ABCSG 45
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Reinovax Biologics Co.,LTD
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)
- Status
- active
- Trials
- 1